My name is Caterina Conte. I'm a professor of medicine at San Raffaele Roma University in Rome, and I do my clinical practice and research activities at IRCCS MultiMedica in Milan, Italy, as well. And I'd say the overarching goal of this collaboration is to support the medical community in addressing critical areas and to promote excellence in diabetes care and research. This collaboration between the EASD and the Sri Lanka College of Endocrinologists for SLENDO 2024 Congress was rooted in our mutual commitment to addressing the significant and growing challenge of diabetes in the Southeastern Asian region and globally, in general, for the burden of diabetes continues to grow, underscoring the need for greater collective action. And this partnership was focussed on sharing knowledge that can lead to improved diagnosis, management and prevention of diabetes complications, importantly, without placing blame on people living with diabetes. I gave two presentations at SLENDO 2024. And in these presentations, I addressed two key topics: incretin-based therapies and the mechanisms of SGLT2 inhibitors. For the first talk on incretin-based therapies, I focussed on the long-term benefits and safety of these drugs, which are paramount in the context of long-term use. And the discussion centred on how incretin-based therapies provide sustained glycaemic control with added cardiovascular and renal benefits. And I also touched upon the potential risks of excess loss of muscle mass during weight loss, which is a hot topic now and a crucial consideration when managing patients over time. In the other session, the one on SGLT2 inhibitors, so these drugs have significantly improved cardiovascular and renal outcomes, leading to major shifts in the medical management of several categories of patients. And this is similar somehow to how statins revolutionised the cardiovascular care by reducing the risks associated with atherosclerotic disease. There are several potential mechanisms. Not all of them have been clarified so far, but, for sure, there is, of course, the glucose lowering action, which is very important in the context of diabetes management, but is not the only mechanism of action. There is also a reduction in the preload, as, for example, in heart failure. So this is also important. And it looks like there are additional mechanisms, such as the reduction of oxidative stress, and also the natriuresis, of course, and the diuretic effects of these drugs. So there are several potential mechanisms that underlie the benefits of these drugs that are, actually, difficult to summarise in just a few minutes. However, as also Chantal Mathieu highlighted in a discussion we had on this topic, a discussion we had on this topic, while SGLT2 inhibitors are generally well tolerated and relatively safe they do have some side effects that require consideration. And, although rare, there are some potentially serious risks, such as euglycaemic ketoacidosis. So it is very important for healthcare providers to be aware and inform patients about these potential risks to ensure informed decision-making and also safety. The hospitality was very warm and we were immersed in local traditions, and the interaction with our hosts was great. And so this also added a rich cultural dimension to the scientific exchange. And this combination made really SLENDO 2024 a memorable experience to me. And I was really, really honored and happy to have the opportunity to participate in this conference.